Jefferies reiterates Illumina stock Hold rating on innovation potential

Jefferies maintained a Hold rating on Illumina (ILMN) with a $235 price target, citing innovation in SomaSeq and TruPath. The stock is up 80% year-over-year. Q3 2026 earnings beat estimates, with revenue of $1.17B and EPS of $1.44. Evercore ISI raised its target to $200 but kept an Underperform rating. ILMN's gross margin is 68% on $4.5B revenue, though some analysts cut earnings estimates.

Original reporting
Published Nov 16, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ILMN
Bullish
high confidence
Mentioned
$ILMN
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ILMNBullishMed
01

Why it matters

Analyst rating and target provide a fresh data point for traders; the price gap may attract buying interest.

02

Market read

New analyst rating offers a modest trading edge for ILMN; broader market impact is minimal.

03

What to watch

Early adoption of SomaSeq and TruPath could accelerate revenue if pilots convert to commercial sales.

Relevance 6/10Novelty 6/10Timing: today

Background

Jefferies' reiteration follows a recent tour of Illumina's facilities and a strong Q3 earnings beat.

Company-level read

Ticker impact

$ILMNBullishHigh confidence
Context

Jefferies reiterated a Hold rating on Illumina with a $235 price target after touring its Cambridge facility and noting Q3 earnings beat.

Expected impact

modest upside pressure as the market prices in the higher $235 target versus current $154 price

Evidence & confidence

The rating and target are fresh analyst input; no immediate catalyst but the sizable gap suggests potential upside.

Market effects

May reinforce positive sentiment for the genomics sequencing sector as Illumina remains a benchmark.

Limited to US biotech equities.

Low; impact confined to Illumina and peers.

Counterpoint

The Hold rating suggests limited upside; investors may wait for clearer growth catalysts.

Key entities

  • Illumina Inc.

    US-listed genomics sequencing firm.

  • Jefferies

    Equity research firm issuing the Hold rating.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.